Search
Lutetium Lu 177 dotatate
go.drugbank.com/drugs/DB13985ApprovedInvestigationalPatients with GEP-NETs have limited second-line treatment options after the metastasis of tumors and inadequate therapeutic response from first-line therapies. … In a clinical trial involving patients with advanced somatostatin receptor-positive GEP-NET, the treatment of Lutetium Lu 177 dotatate in combination with octreotide resulted in longer progression-free
Categories: Compounds used in a research, industrial, or household settingSynonyms: Lu-DOTATATE, [177]Lu-DOTA-TATEAtezolizumab
go.drugbank.com/drugs/DB11595ApprovedInvestigationalAtezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. … [A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsManganese gluconate
go.drugbank.com/drugs/DB11141ApprovedManganese gluconate is a direct ingredient in food substances as a nutrient supplement. In pharmaceutical preparations it is used as a [DB06757] supplement. … It is typically obtained by reacting manganese carbonate with gluconic acid in aqueous medium and then crystallizing the product to form a slightly pink powder.
Mixtures: Cal-mag Plus K, Mn and Zn Caplets, Vitamin E 400 Iu With Selenium, Vitamin C & ManganeseSynonyms: Manganese(II) gluconate, Manganese D-gluconateOmega-3 fatty acids
go.drugbank.com/drugs/DB11133ApprovedInvestigationalNutraceuticalThe three types of omega-3 fatty acids involved in human physiology are α-linolenic acid (ALA) (found in plant oils), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) (both commonly found in … Omega-3 fatty acids play a critical role in metabolism and cellular function and they are available as daily supplements. On September 8, 2004, the U.S.
Mixtures: Animi-3 with Vitamin D, LIPOPLUS 20% ( EMULSION PARA PERFUSION IV.)Synonyms: n-3 PUFAs, n-3 fatty acidsFamtozinameran
go.drugbank.com/drugs/DB17088ApprovedInvestigationalThe Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. … It is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.4/BA.5.[L43907,L43912]
Mixtures: Comirnaty Original & Omicron Ba.4/ba.5, Comirnaty Original & Omicron Ba.4/ba.5Helium
go.drugbank.com/drugs/DB09155ApprovedInvestigationalVet approvedHelium is a second most abundant chemical element in the universe with symbol He and atomic number 2. … It is a colorless, odorless, tasteless, non-toxic, inert, monatomic gas located at the top of the noble gases on the periodic table.
Mixtures: Oxygen In Helium Mix, Oxygen In Helium MixtureSertindole
go.drugbank.com/drugs/DB06144ApprovedWithdrawnIt is a phenylindole derivative used in the treatment of schizophrenia. … It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects.
Categories: Dopamine D2 Receptor AntagonistsVinflunine
go.drugbank.com/drugs/DB11641ApprovedInvestigationalIn 2009, vinflunine was approved by the European Medicines Agency (EMA) as a second-line therapy of metastatic and advanced urothelial cancer after failure of platinum-based treatment [A32626]. … Vinflunine is a third-generation member of the vinca alkaloid family with anti-tumour actions. It was first described in 1998 at the Pierre Fabre research center in France.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexDuvelisib
go.drugbank.com/drugs/DB11952ApprovedInvestigationalAll the work around duvelisib showed that this agent is a potent inhibitor of both forms.[A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585] … Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma
Cangrelor
go.drugbank.com/drugs/DB06441ApprovedInvestigationalCangrelor was approved by the FDA in June 2015 for intravenous application. … An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset